Here are three things to know.
1. The single dose antibiotic is intended to treat bacterial vaginosis, the most common gynecologic infection in the country.
2. Solosec is the first oral antibiotic approved for the infection in more than a decade.
3. Symbiomix expects the drug to hit the market in the first quarter of 2018.
More articles on supply chain:
NIH issues $15M in grants for development of 3-D human tissue models
Biosimilars are getting approved, but few have hit the market — here’s why
6 drugmakers in the headlines
